Keeping the Patient at the Core of our Work
As an organization, MorphoSys places great importance on our ongoing partnership and engagements with patients, caregivers, and advocacy groups. Their experiences are critical to informing new pathways that can address patient needs and fulfill our mission: More life for people with cancer.
Our approach to infusing the patient perspective into our company is simple but comprehensive: we incorporate patient and caregiver voices across all aspects of our drug development – from mapping out the earliest stages to designing clinical trials to navigating regulatory processes and beyond. This integration is crucial to our success – because to address patients’ needs, we need to truly understand what those needs are.
“We always want to be included in the development of medicines to gather patient insights from the very beginning. Getting those insights early on offers sponsors the potential to design a trial that could enroll faster and clearly demonstrate the need for options to regulatory authorities.”
Christine Verini, Chief Executive Officer, CancerCare
To successfully partner with patient communities, we strive to communicate with honesty and transparency, regularly seeking, hearing and incorporating patient and caregiver feedback to drive meaningful outcomes. To this end, we focus on
four priorities with our advocacy group partners:
1. Education
Advocacy groups provide critical education, helping patients and caregivers understand their diseases and the latest innovations in the field. For example, they will play a key role in helping people understand the potential benefits that could result from treating myelofibrosis with a combination therapy versus monotherapy.
2. Engagement
Advocacy groups help us tailor medicines to the patients who need them. For example, we work closely with advocacy groups throughout our clinical development – from trial design and patient and site selection to providing regular updates and results as the trial progresses.
3. Access
By working closely with advocacy groups, we’re able to reach more patients in need, even after bringing a new medicine to market. Because clinical milestones will remain just data points if patients can’t access these potential lifechanging medicines.
4. Champions
By bringing patients and caregivers to share their stories with our teams, we’re able to champion their voices in ways that are authentic and respectful to their experience and inspire colleagues to deliver on our mission.
Our successful record of partnering with advocacy groups – from facilitating clinical development collaborations to hosting patient speakers at conferences – motivates us to keep working diligently on innovative solutions for cancer care.
For us, it’s simple: strengthening our partnerships with advocacy groups means MORE commitment to patients and caregivers.
Fullscreen
Close
Download